ISSN: 2161-0681

Journal of Clinical & Experimental Pathology
Open Access

Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)
Google Scholar citation report
Citations : 1437

Journal of Clinical & Experimental Pathology received 1437 citations as per Google Scholar report

Journal of Clinical & Experimental Pathology peer review process verified at publons
Indexed In
  • Index Copernicus
  • Google Scholar
  • Sherpa Romeo
  • Open J Gate
  • Genamics JournalSeek
  • JournalTOCs
  • Cosmos IF
  • Ulrich's Periodicals Directory
  • RefSeek
  • Directory of Research Journal Indexing (DRJI)
  • Hamdard University
  • EBSCO A-Z
  • OCLC- WorldCat
  • Publons
  • Geneva Foundation for Medical Education and Research
  • Euro Pub
  • ICMJE
  • world cat
  • journal seek genamics
  • j-gate
  • esji (eurasian scientific journal index)
Share This Page

Boldrini L

Department of Surgical, Medical, Molecular Pathology and Critical Area, University of Pisa, Pisa, Italy

Biography

Boldrini L is currently working as a Professor in the Department of Pathology, Molecular Pathology and Critical Area, University of Pisa, Pisa, Italy.The author's research interests include Clinical Pathology, Histopathology, Hemato Pathology, Surgical Pathology, Diagnosis. The author is serving as an editorial member and reviewer of several international reputed journals. The author has successfully completed his administrative responsibilities. The author has authorized many research articles/books related to Clinical Pathology, Experimental Pathology
Publications

TERT Promoter Mutations and Tert Expression in Early-Stage (T1N0M0) Non-Small Cell Lung Cancer (NSCLC)

Background: The mutations detected in the promoter of the telomerase reverse transcriptase (TERT) gene,namely C228T and C250T, were first identified in melanoma and subsequently in several cancer models, notably glioma, thyroid cancer and bladder cancer. Recent findings demonstrate that mutation of the TERT promoter may be one of the most common ge... Read More»

Giordano M, Macerola E, Boldrini L, Giannini R, Servadio A, Alì G, Melfi F, Lucchi M, Bertoglio P, Mussi A and Fontanini G

Research Article: J Clin Exp Pathol 2015, 5: 248

DOI: 10.4172/2161-0681.1000248

Abstract Peer-reviewed Full Article Peer-reviewed Article PDF Mobile Full Article

Top